• The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer

  NCT05555901

  Unknown statusInterventionalPhase 2Updated Aug 30, 2023
• Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer

  NCT07051785

  Not yet recruitingInterventionalPhase 2Updated Jul 4, 2025
• Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

  NCT05447715

  Unknown statusInterventionalPhase 2Updated Jul 7, 2022
• The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

  NCT05634590

  Unknown statusInterventionalPhase 2Updated Dec 2, 2022
• Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer

  NCT07286695

  Not yet recruitingInterventionalPhase 2Updated Jan 21, 2026
• Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

  NCT07042685

  RecruitingInterventionalPhase 2Updated Apr 9, 2026

ClinicalTrials.gov ID

NCT07150403

Lead Sponsor

Federation Francophone de Cancerologie DigestiveOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

74Estimated

Last Update Posted

Sep 8, 2025Actual

Start Date

Dec 31, 2025Estimated

Primary Completion Date

Feb 28, 2028Estimated

Completion Date

Oct 31, 2028Estimated

Official Title

A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Brief Summary

The standard second-line treatment for metastatic colorectal cancer (mCRC) involves chemotherapy (FOLFOX or FOLFIRI) combined with an antiangiogenic agent, such as bevacizumab or aflibercept. Maintaining VEGF inhibition between first and second-line treatments has shown modest clinical benefits, with exploratory analyses suggesting that bevacizumab is more effective in smaller tumors. The ULYSSE trial aims to evaluate the efficacy and safety of Fruquintinib, a potent antiangiogenic agent, combined with a doublet chemotherapy (FOLFOX or FOLFIRI) in second-line treatment for BRAF wild-type, MSS mCRC patients who have failed prior treatment.

• Metastatic Colorectal Carcinoma (mCRC)

• Oxaliplatin intravenous
• 5 FU bolus
• Folinic acid
• 5 FU continuous
• Irinotecan
• FRUQUINTINIB
• BEVACIZUMAB

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• - Age ≥ 18 years and ≤ 80 years; provided the score of the G8 geriatric questionnaire is >14 for patients 75 years or older
• Patients with a histologically confirmed diagnosis of metastatic colorectal cancer (mCRC), with a documented disease progression (as per RECIST v1.1, assessed by the investigator and confirmed through CT or MRI).
• Patients must have previously received first-line therapy with Bevacizumab or an EGFRi, in combination with either FOLFOX or FOLFIRI, for non-resectable mCRC. Patients who progressed during the adjuvant chemotherapy (FOLFOX) or within the 6 months following its completion are eligible for inclusion
• Patients must have an unresectable tumor at the time of enrollment.
• Patients must have at least one measurable/evaluable metastatic lesion according to RECIST v1.1 criteria; images have to be available for collection
• Metastases not amenable to surgery and/or thermo-ablation and/or stereotaxic radiotherapy
• WHO performance status 0 or 1
• Available parameters to compute the SPOD score: WHO PS, hemoglobin, platelet count, WBC/absolute neutrophil count ratio, lactate dehydrogenase (LDH), alkaline phosphatase, and the number of metastatic sites.
• Adequate liver functions: Total Bilirubinemia < 2,5 ULN, AST and ALT ≤ 5 ULN
• Adequate hematological (Hemoglobin ≥10g/dL, platelets ≥100G/L, neutrophils ≥1.5G/L) and renal (creatinine clearance ≥ 50 mL/min according to CKD-EPI) functions
• Proteinuria < 2+ (dipstick urinalysis) (if 2+ or more, proteinuria must be ≤1g/24hour)
• Life expectancy ≥ 3 months
• Women of childbearing potential must agree to use a highly effective method of contraception during the trial and for at least 15 months after discontinuation of the experimental treatments. Men who have sexual relations with women of childbearing potential must agree to use contraception during treatment and for at least 12 months after discontinuation of the experimental treatments
• Ability of the patient to understand, sign and date the information note and informed consent form before any study specific procedures
• Patient affiliated to a social security scheme
• Available tumor sample and pathology report for collection

Exclusion Criteria:

• - Patients who have received more than one prior systemic therapy

• FOLFIRINOX Regimen +/- targeted therapy in the first line setting

• Unknown RAS status

• BRAF V600E mutated tumor

• MSI/dMMR tumor

• Known brain metastasis

• Known peritoneal carcinomatosis if there are signs of clinical occlusion or sub-occlusion

• History of gastric ulceration, or myocardial infarction, or severe coronaropathy or severe cardiac dysfunction, within the past 6 months prior to treatment start

• Patients with dihydropyrimidine dehydrogenase deficiency (uracilemia ≥ 16 ng/mL)

• Hypersensitivity to one of the study drugs or one of its excipients

• Inability to swallow capsules

• Live attenuated vaccines 30 days prior to treatment start

• Untreated bone fracture

• Significant haemorrhagic diathesis or coagulopathy (in the absence of anti-coagulant treatment)

• Major surgery, open biopsy or major traumatic lesion in the prior 30 days or the need for major surgery during the trial

• Pregnant or breastfeeding woman or patients with no adequate contraception

• Known Uridine Diphosphate Glucuronyltransferase (UGT1A1) deficiency or known Gilbert disease

• Strong inducers of CYP3A4 (treatment with St John's Wort (Hypericum perforatum), fampicin, phenobarbital, primidone, phenytoin and carbamazepine)

  -- Strong inhibitors of CYP3A4, continuous use of azole antifungals (posaconazole, voriconazole, itraconazole, isavuconazole), ritonavir, verapamil, diltiazem, grapefruit juice (equivalent to half a fresh grapefruit/day)

• Concomitant or recent treatment with sorivudine or its analogs (including brivudine) within 4 weeks prior to the administration of protocol treatment (related to Fluorouracil)

• Concomitant treatment with phenytoin or its analogs

• QT/QTc interval > 450 ms for men and > 470 ms for women

• Uncontrolled hypertension (defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg) or history of hypertensive crisis (TA systolic> 20 mmHg) or hypertensive encephalopathy

• History of veinous thromboembolic events, including deep vein thrombosis and pulmonary embolism, within the past month prior to study enrollment

• History of stroke and/or transient ischemic attack (TIA) within the past 12 months

• Residual Oxaliplatin neuropathy (grade ≥ 2) counter indicates FOLFOX administration

• Persistence of clinically significant symptoms after a thromboembolic event despite anticoagulant treatment

• Arterial thromboembolism (myocardial infarction, stroke, transient ischemic attack) occurring under antiangiogenic therapy

• Other active cancers or history of cancer treated within the last 5 years except for carcinoma in situ of the cervix or basal cell or squamous cell skin carcinoma or any other carcinoma in situ, considered cured

• Persons deprived of liberty or under guardianship or unable of giving consent

• Inability to undergo the medical follow-up of the trial for geographical, social or psychological reasons

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Federation Francophone de Cancerologie DigestiveOTHER

drbhuguenin@orange.fr

alvilling@ch-auxerre.fr

a.peytier@ch-ab.fr

faudemar@ch-cotebasque.fr

h.ammarguellat@ch-beauvais.fr

aelkaddissi@chu-besancon.fr

laurent.basson@ichf.fr

s.pernot@bordeaux.unicancer.fr

v.cochin@tivoli-oncologie.fr

marc.kanaan@ch-chauny.fr

thomas.davieau@ch-cholet.fr

kais.aldabbagh@stcome.com

jbaisenfarb@iadonco.org

Candice.CarolaDelvallez@ghpso.fr

cgiraud@clinique-psv.fr

jean-louis.jouve@chu-dijon.fr

adrouillard@icb-cancer.fr

margot.laly@ght85.fr

fwatelle@ch-lens.fr

benoist.chibaudel@ihfb.org

leaclavel1@gmail.com

laetitia.dahan@ap-hm.fr

morgan.andre@ch-mdm.fr

benjamin.linot@groupeconfluent.fr

odubreuil@hopital-dcss.org

julien.taieb@aphp.fr

jean-baptiste.bachet@aphp.fr

thomas.aparicio@aphp.fr

david.tougeron@chu-poitiers.fr

dbotsen@chu-reims.fr

obouche@chu-reims.fr

caroline.cheneau@icrb.fr

sandrine.hiret@ico.unicancer.fr

catherine.ligeza@hospigrandouest.fr

j.marc.phelip@chu-st-etienne.fr

a.bodere@ch-stmalo.fr

lm.dourthe@solcrr.org

f-pommeret@ch-hopitauxduleman.fr

netchepare@ch-valence.fr

m.muller7@chru-nancy.fr

bomorel@hno.fr

valerie.boige@gustaveroussy.fr